Wellington Management Group LLP Purchases 19,932 Shares of Liquidia Co. (NASDAQ:LQDA)

Wellington Management Group LLP boosted its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 12.5% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 179,923 shares of the company’s stock after acquiring an additional 19,932 shares during the quarter. Wellington Management Group LLP owned approximately 0.23% of Liquidia worth $1,799,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Quest Partners LLC bought a new position in shares of Liquidia during the 2nd quarter valued at $27,000. Clear Harbor Asset Management LLC bought a new position in Liquidia during the third quarter valued at about $100,000. Signaturefd LLC raised its holdings in Liquidia by 38,400.0% during the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock valued at $100,000 after buying an additional 9,984 shares in the last quarter. Ballentine Partners LLC acquired a new stake in shares of Liquidia in the third quarter worth about $110,000. Finally, Whitcomb & Hess Inc. boosted its stake in shares of Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock worth $116,000 after acquiring an additional 1,074 shares in the last quarter. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Liquidia

In related news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the sale, the chief executive officer now owns 812,193 shares of the company’s stock, valued at $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Michael Kaseta sold 3,892 shares of the stock in a transaction dated Monday, October 14th. The stock was sold at an average price of $11.11, for a total transaction of $43,240.12. Following the completion of the transaction, the chief financial officer now directly owns 311,076 shares of the company’s stock, valued at $3,456,054.36. This trade represents a 1.24 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,007 shares of company stock worth $245,780 over the last three months. Company insiders own 30.10% of the company’s stock.

Liquidia Stock Performance

Shares of LQDA opened at $10.69 on Thursday. The company has a 50-day simple moving average of $10.93 and a 200-day simple moving average of $11.21. Liquidia Co. has a 52 week low of $7.62 and a 52 week high of $16.99. The firm has a market capitalization of $904.77 million, a P/E ratio of -6.56 and a beta of 0.22.

Analyst Ratings Changes

Several research firms recently weighed in on LQDA. Scotiabank started coverage on Liquidia in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $30.00 target price for the company. Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Liquidia in a report on Thursday, November 14th. Lifesci Capital started coverage on shares of Liquidia in a report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Liquidia in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $24.00.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).